NantKwest (NASDAQ:NK) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Tuesday.
Separately, Zacks Investment Research upgraded shares of NantKwest from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Saturday, January 6th. Three equities research analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. The company currently has an average rating of “Hold” and an average price target of $4.00.
Shares of NASDAQ:NK opened at $4.01 on Tuesday. The company has a market cap of $301.11, a PE ratio of -3.34 and a beta of 2.83. The company has a quick ratio of 6.35, a current ratio of 6.35 and a debt-to-equity ratio of 0.01. NantKwest has a twelve month low of $2.71 and a twelve month high of $8.45.
Hedge funds have recently added to or reduced their stakes in the stock. Ardsley Advisory Partners purchased a new stake in NantKwest in the 4th quarter valued at $112,000. Russell Investments Group Ltd. purchased a new stake in NantKwest in the 3rd quarter valued at $139,000. JPMorgan Chase & Co. raised its position in NantKwest by 155.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 25,579 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 71,444 shares during the last quarter. SG Americas Securities LLC raised its position in NantKwest by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 49,356 shares of the biotechnology company’s stock valued at $270,000 after purchasing an additional 35,424 shares during the last quarter. Finally, Deutsche Bank AG raised its position in NantKwest by 116.7% in the 4th quarter. Deutsche Bank AG now owns 67,847 shares of the biotechnology company’s stock valued at $304,000 after purchasing an additional 36,542 shares during the last quarter. Hedge funds and other institutional investors own 15.89% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/17/nantkwest-nk-upgraded-to-sell-at-bidaskclub.html.
NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.